RESEARCH ARTICLE

Identification of common and divergent gene expression signatures in patients with venous and arterial thrombosis using data from public repositories

Bidossessi Wilfried Hounkpe 1, Rafaela de Oliveira Benatti 1, Benilton de Sá Carvalho 2, Erich Vinicius De Paula 1,3 *

1 School of Medical Sciences, University of Campinas, Campinas, SP, Brazil, 2 Department of Statistics, Institute of Mathematics, Statistics and Scientific Computing, University of Campinas, Campinas, SP, Brazil, 3 Hematology and Hemothrapy Center, University of Campinas, Campinas, SP, Brazil

☯ These authors contributed equally to this work.
* erich@unicamp.br

Abstract

Cardiovascular disease (CVD) and venous thromboembolism (VTE) figure among the main causes of morbidity and mortality in modern societies. Although associated with distinct pathogenic mechanisms, epidemiological, experimental and clinical trial data suggest that the mechanisms responsible for arterial and venous thrombosis are at least partially overlapped. Herein we aimed to explore shared and discordant pathways involved in the pathogenesis of VTE and CVD at the transcriptomic level and to validate the results in independent cohorts. Five public datasets of gene expression data from VTE and CVD (myocardial infarction, peripheral arterial occlusive disease and stroke) patients were analyzed using an integrative bioinformatic strategy. A machine/statistical learning method was used to derive classifiers for the discrimination of VTE and CVD at the transcriptomic level and to validate the results in independent cohorts. Two sets of genes that were commonly (n = 472) or divergently (n = 124) expressed in CVD and VTE were identified. Genes and pathways associated with innate immune function were over-represented in both conditions, along with pathways associated with complement and hemostasis. Pathways associated with neutrophil activation and with IL-1 signaling were also enriched in CVD compared to VTE. The gene expression signature of VTE more closely resembled the pattern of cardioembolic stroke than the patterns of acute myocardial infarction, ischemic stroke and peripheral arterial occlusive disease. Classifiers derived from these gene lists accurately discriminated patients with VTE and CVD from independent cohorts. In conclusion, our results add a new set of data at the transcriptomic level for future studies between arterial and venous thrombosis.

Strengths and limitations of this study

- Our results represent the first comparison of venous and arterial thrombosis at the transcriptomic level.
- Our main result was the demonstration that immunothrombosis pathways are important to the pathophysiology of these conditions, also at the transcriptomic level.
A specific signature for venous and arterial thrombosis was described, and validated in independent cohorts.

The limited number of public repositories with gene expression data from patients with venous thromboembolism limits the representation of these patients in our analyses.

In order to gather a meaningful number of studies with gene expression data we had to include patients in different time-points since the index thrombotic event, which might have increased the heterogeneity of our population.

Introduction

CVD is a generic term that encompasses conditions caused by arterial thrombosis such as myocardial infarction (MI), ischemic stroke (IS) and peripheral arterial obstructive disease (PAOD), with the former two representing the most frequent causes of years of life lost in most regions of the world [1, 2]. Venous thromboembolism (VTE) encompasses deep vein thrombosis (DVT) and pulmonary embolism (PE), which together represent the third leading cause of vascular disease in the world [3]. Although it has been long recognized that the pathogenesis of these two conditions are based on distinct cellular and molecular pathways, the existence of common pathogenic pathways contributing to both CVD and VTE is suggested by (i) the sharing of risk factors such as obesity, smoking, hypertriglyceridemia [4]; (ii) the epidemiological association between CVD and VTE illustrated by the higher prevalence of CVD in patients with VTE even years after the venous event [5–7]; (iii) the fact that some inflammatory diseases such as sickle cell disease and antiphospholipid syndrome (APS) increase the risk of both conditions [8, 9]; and, (iv) more recently, the demonstration that treatment strategies classically used for CVD can also benefit patients with VTE [10, 11], and vice versa [12]. In this context, a lot remains to be learned about their shared and independent pathological mechanisms, whose identification could contribute to the identification of new therapeutic targets for both VTE and CVD [7, 13, 14].

Three major frameworks have been used to address differences and similarities between CVD and VTE: (i) studies in animal models, (ii) histopathological analyses of thrombi, and (iii) epidemiological data. Studies in animal models identified proteins and cells that contribute to VTE or CVD [2, 15–17] allowing the development of important therapeutic targets for each condition. However, these studies have not focused on the relative contribution of these pathways to CVD, VTE or both conditions in human disease. While histopathological studies of human thrombin initially supported the classical paradigm of white (platelet-rich) or red (fibrin- and red blood cell-rich) thrombi in CVD and VTE respectively, these conclusions were later challenged by several studies showing a much more complex picture, as recently reviewed [13]. Lastly, epidemiological studies have been instrumental to gain insights into the association of venous and arterial thrombosis, and clearly demonstrated that VTE and CVD are indeed associated conditions [18, 19]. However, these studies have not been yet able to clearly define the mechanism of this association, whether causal (i.e. atherosclerosis leads to VTE) or driven by common pathogenic mechanisms [7].

In recent years, the availability of large databases of genomic data, along with bioinformatics and machine learning tools capable of performing integrative and functional analyses of these datasets allowed new strategies for the research about the molecular and cellular pathogenesis of complex conditions. In particular, publicly available datasets from gene expression studies, once performed to define specific disease signatures, can now be compared, grouped...
and meta-analyzed, allowing biases and artefacts to be canceled out between datasets, so that true relationships are more likely to stand out [20–26]. Herein we used a panel of bioinformatics and machine learning tools to explore the differences and similarities between VTE and CVD, thus contributing with a new layer of data to our understanding of the common and divergent pathogenic mechanisms of two conditions of high epidemiological relevance.

Methods

Identification of eligible studies and datasets

Gene expression datasets from microarray studies including human patients with CVD or VTE were searched in the public repository Gene Expression Omnibus (GEO) [27], maintained by the NCBI, by May 2018. Search was conducted using the terms “venous thrombosis”, “venous thromboembolism”, “myocardial infarction”, “stroke”, “coronary ischemia”, “angina”, “atherosclerosis”, “peripheral arterial disease” or “thrombosis”. Datasets were included if they met all the following inclusion criteria: (1) microarray data obtained from human samples using the same microarray platform; (2) RNA source restricted to whole blood or populations of circulating blood cells; (3) studies including both affected patients and healthy controls, so that the differential expression of each gene was evaluated under the same experimental conditions; (4) availability of metadata allowing the separation of venous from arterial events; and (5) datasets from studies published in peer-reviewed journals. In the course of our study, we also restricted our analysis to studies using the same microarray platform, so as to limit heterogeneity.

Patient and public involvement

No patient involved.

Meta-analysis of gene expression studies

Pre-processing. Microarray raw data were pre-processed using the Robust Multichip Average (RMA) method [28] implemented in the oligo package [29]. For each dataset, the algorithm performs background subtraction, minimizing the effects of optical noise and non-specific binding on the estimation of relative gene expression parameters. Later, quantile normalization was applied, mitigating the effects of technical variables through the estimation of a common intensity distribution across samples. This stage was followed by a median-polish step, which summarized the several probe intensity measurements into a single probeset log-expression quantity, for the downstream meta-analysis step. Using the biomaRt package [30], we annotated the probesets with their respective Ensembl Gene IDs.

Meta-analysis. To perform the meta-analysis, expression data were organized following their pre-defined classes and study of origin. Meta-analysis was performed with RankProd package [31]. The algorithm of this package adapts the rank production method initially designed to single experiment analysis to integrate multiple origin studies. It is a non-parametric method that detects genes consistently ranked as DE by comparing patients to healthy controls across datasets. One hundred permutations were performed to compute the p-value and the false discovery rate (FDR). The gene list was further filtered to include only genes that were up- or down-regulated in the same direction in all five studies based on a false discovery rate (FDR) < 0.05.

Correlation analysis of gene expression levels in CVD and VTE

The correlation between the expression levels of genes identified in the meta-analysis between VTE and CVD was expressed using the estimated Pearson’s coefficient, and then represented
Functional gene set analyses
To facilitate the interpretation of the biological significance of the gene list identified by the meta-analysis, a functional gene set analysis (GSA) was performed using EnrichR, a bioinformatics web-based tool that includes several curated GSA libraries encompassing pathway enrichment analysis (e.g. KEGG, Reactome, and 18 other libraries), gene ontologies (for cellular components, biological process, molecular function), among others. Of the list of enriched terms identified by EnrichR, only pathways that were (i) listed among the 10 most significant (based on the p-value) for each library, and (ii) identified in at least two libraries from the same category were considered. For gene ontology terms, the top 5 terms with an adjusted p-value < 0.0001 were included.

Evaluation of genes with divergent expression between VTE and CVD
A list of genes with divergent expression between VTE and three databases of CVD (IS, AMI and PAOD) was obtained by selecting all genes with a fold-change higher than 1.5 that were up-regulated in VTE and down-regulated in IS, AMI and PAOD; as well as genes with a fold-change lower than 0.8 that were down-regulated in VTE and up-regulated in IS, AMI and PAOD. The cutoff values are defined as the percentile 25% (0.8) and 75% (1.49~1.5) fold change to prioritize the most down and up-regulated genes respectively. Similar filtering approach has been used to avoid the definition of arbitrary threshold [33–35].

These gene lists were used for an additional functional analysis based on FAIME (Functional Analysis of Individual Microarray/RNAseq Expression) scores. The FAIME algorithm is implemented in seq2pathway package [36] and computes the cumulative quantitative effects of genes inside differentiated Gene Ontology terms using log2 gene expression of each individual sample. The result was clustered based on their gene pattern similarities using Euclidean distances and plotted in a FAIME score heat map.

Validation of gene expression signatures associated with VTE and CVD
In order to validate our results in independent cohorts, we first used Support Vector Machine (SVM) based methods to identify two subsets of genes capable to more accurately separate VTE from CVD (validation 1) and VTE (validation 2) as well as AMI and IS (validation 3 and 4) from controls. SVM-based models are based on statistical learning theory [37], and are normally used to optimize the discriminatory power of complex datasets by identifying subsets of data with higher discriminatory potential (classifiers) [38, 39]. For validation 1, SVM was applied to the list of genes that were divergently expressed between VTE and CVD, using the VTE and AMI patients’ datasets employed for our meta-analysis as training cohorts. The list of classifiers was then tested in three additional cohorts (validation cohorts) that were not used in the meta-analysis, constituted of patients with VTE (GSE48000) [40], AMI (GSE59867) [41]. For validation 2, the training cohort consisted of the dataset of VTE patients used in our meta-analysis (GSE19151), and the validation cohort consisted of a different dataset of VTE patients (GSE48000) [40]. Finally a training cohort for validation 3 and 4 consisted healthy controls and patients of the AMI and IS datasets (GSE59867, GSE22255 respectively). Results were then validated using the cohorts consisted of another AMI and IS datasets (GSE141512 and GSE16561 respectively) and presented as heat map [42] of normalized expression.
Results

Studies included in the meta-analysis

Five studies fulfilled the inclusion and exclusion criteria described in methods section, and were included in the meta-analysis. These studies included data from 163 adult patients and 145 healthy controls. Table 1 provides the details of each study. As shown in Table 1, only one study include patients with VTE and compared gene expression levels in patients with single or recurrent VTE (GSE19151) with healthy controls [43]. The other four remaining studies involve CVD. These CVD studies present gene expression levels of patients with PAOD (GSE27034) [44], AMI (GSE48060) [45], cardioembolic stroke (GSE58294) [46], and IS (GSE22255) [47]. All of them have appropriated study-specific paired healthy controls.

Similarities in gene expression profiles of arterial and venous thrombosis

The meta-analysis of all studies identified 168 up-regulated and 304 down-regulated DE genes (S1 Table). The top 10 up- and down-regulated genes are shown in Table 2. Since the four studies of CVD included patients in the acute or chronic phases of their disease courses, we also present separate meta-analyses of acute (AMI and CS) and chronic (IS and PAOD) CVD (S2 and S3 Tables).

Next, we assessed the correlation of gene expression levels across all five studies using all 472 DE genes. As shown in Fig 1. VTE presented numerically lower correlation coefficient with IS and PAOD than those observed between all studies involving arterial thrombosis. We also evaluated the correlation of VTE with studies of CVD that included patients in acute and chronic phases separately (S1 Fig).

Based on the lower correlation of gene expression changes between VTE and CVD we interrogated whether an unsupervised cluster analysis using the fold-change of the 472 genes identified in the meta-analysis could provide additional information on differences and similarities between VTE and CVD at a transcriptomic level. As shown in Fig 2 AMI, PAOD and IS were clustered together while the pattern of VTE was closer to CS than to this cluster (AMI, PAOD and IS).

Table 1. Characteristics of individual studies included in our analyses.

| GEO access number | Characteristics of patients/disease included in each dataset | Size (Pt: Ctl) | RNA source |
|-------------------|----------------------------------------------------------|---------------|------------|
| GSE19151          | Adult with one or more prior VTE or warfarin; APS and cancer excluded | 70:63 | Whole blood |
| GSE27034          | Peripheral arterial occlusive disease, defined as ankle:brachial index < 0.9 | 19:18 | PBMC |
| GSE48060          | Adults with 1st time acute myocardial infarction*; inflammatory diseases and cancer excluded. | 31:21 | Whole blood |
| GSE58294          | Adults with cardioembolic stroke (i.e. at least one source of cardiac embolus and exclusion of strokes from other etiologies) † | 23:23 | Whole blood |
| GSE22255          | Adults with history of one ischemic stroke more than 6 months prior to sample collection; anemia and allergies excluded | 20:20 | PBMC |

GEO: Gene Expression Omnibus, Pt:Ctl: patients:controls; PBMC: peripheral blood mononuclear cells; WBC: white blood cells; VTE: Venous thromboembolism; APS: antiphospholipid syndrome.

* Samples were collected with 48h from the acute event
† subset of patients recruited for the Clear Stroke Trial [48]; samples were collected within 3h from the acute event, prior to any pharmacological treatment. All studies used the Affymetrix Human Genome U133 Plus 2.0 as a microarray platform. References for published studies that used these datasets are indicated in the main text.

https://doi.org/10.1371/journal.pone.0235501.t001
The shared gene expression signature between VTE and CVD is markedly associated with innate immunity

To evaluate which pathways and biological processes were associated with the gene expression signature shared between VTE and CVD (472 DEG) we performed a functional analysis using stringent criteria for the call of potentially relevant pathways and gene ontology terms. As shown in Table 3, pathways associated with hemostasis and innate immunity were consistently identified in these analyses.

Evaluation of genes that were divergently expressed between VTE and CVD

While the meta-analysis allowed us to gain insights on the similarities of VTE and CVD, we also wanted to identify the most relevant differences between these two conditions at the gene expression level. In order to do so we obtained a list of all genes whose direction of expression were divergent between venous and arterial thrombosis. In this analysis, CS—which clustered with VTE in the similarity analysis—was not included, so as to sensitize the analysis for differences between venous and arterial thrombosis. In total 124 genes were identified, of which 71 were up-regulated in VTE and down-regulated in CVD, and 53 were up-regulated in CVD.

### Table 2. Top differentially expressed genes identified in the meta-analysis.

| Genes | VTE | PAOD | AMI | CS | IS | Ave FC | FDR |
|-------|-----|------|-----|----|----|--------|-----|
| **Up-regulated genes** |     |      |     |    |    |        |     |
| G0S2  | 1.20| 4.88 | 3.89| 1.12| 1.76| 2.57   | <0.0001|
| BCL2A1| 2.29| 1.55 | 1.73| 1.30| 1.88| 1.75   | <0.0001|
| TNFAIP6| 2.05| 1.45 | 1.72| 1.23| 1.70| 1.63   | <0.0001|
| ANXA3 | 1.71| 1.40 | 1.21| 1.83| 1.96| 1.62   | <0.0001|
| SERPINB2| 1.19| 1.91 | 1.42| 1.23| 1.95| 1.54   | <0.0001|
| SI00A12| 2.10| 1.00 | 1.01| 1.74| 1.79| 1.53   | <0.0001|
| SLPI  | 1.84| 1.14 | 1.00| 1.59| 1.65| 1.45   | <0.0001|
| FKBP1B| 2.05| 1.19 | 1.23| 1.09| 1.61| 1.43   | <0.0001|
| DEFA4 | 1.25| 1.55 | 1.27| 1.01| 2.08| 1.43   | <0.0001|
| PTX3  | 1.06| 1.98 | 1.56| 1.11| 1.35| 1.41   | <0.0001|
| **Down-regulated genes** |     |      |     |    |    |        |     |
| CLIC3 | 0.89| 0.77 | 0.89| 0.87| 0.92| 0.87   | <0.0001|
| BACH2 | 0.92| 0.91 | 0.79| 0.89| 0.96| 0.90   | <0.0001|
| TXK   | 0.85| 0.94 | 0.93| 0.87| 0.63| 0.84   | <0.0001|
| MLC1  | 0.87| 0.97 | 0.98| 0.94| 0.97| 0.95   | <0.0001|
| ID3   | 0.94| 0.92 | 0.90| 0.84| 0.97| 0.91   | <0.0001|
| ZNF304| 0.87| 0.98 | 0.91| 0.97| 0.61| 0.87   | <0.0001|
| EVL   | 0.97| 0.95 | 0.92| 0.87| 0.86| 0.92   | <0.0001|
| BCOR  | 0.93| 0.96 | 0.92| 0.95| 0.92| 0.94   | <0.0001|
| TBX21 | 0.98| 0.96 | 0.79| 0.97| 0.79| 0.90   | <0.0001|
| IL2RB | 0.87| 0.95 | 0.92| 0.94| 0.87| 0.91   | <0.0001|

Genes were ranked according to the fold change. FC: Fold-change; Ave FC: average FC; FDR: False Discovery Rate. VTE: venous thromboembolism; PAOD: peripheral arterial obstructive disease; AMI: acute myocardial infarction; CS: cardioembolic stroke; IS: ischemic stroke; Innate Imm: innate immunity; Imm Reg: Immune regulation; Cell Maint: cell maintenance; Cell Prolif: cell proliferation; Gene expr: gene expression; T cell dev: T cell development. The average FC is expressed as mean FC across studies.

https://doi.org/10.1371/journal.pone.0235501.t002
and down-regulated in VTE (S4 Table). Expression levels of these genes are shown in Fig 3 which clearly demonstrates a different profile between VTE and CVD.

We then identified which pathways were associated with the expression signatures of these 124 genes. As shown in Fig 4A, genes that were up-regulated in VTE compared to CVD associated mainly with biological processes related to cell maintenance, cell proliferation and immune regulation. In contrast, genes that were up-regulated in CVD compared to VTE were associated mainly with innate immunity, neutrophil degranulation and cell proliferation (Fig 4B).

### Validation of gene expression signatures associated with VTE and/or CVD

Finally, we validated the biological relevance of these gene expression signatures by constructing three SVM-based gene lists (classifiers) including one of the most informative genes from the list of divergently expressed genes (n = 124), and two from the commonly expressed genes (n = 472) (validation 1, 2, 3 and 4, respectively). The classifiers are presented in S5 Table. In validation 1, we were able to demonstrate that a classifier consisting of 107 genes could discriminate patients with at least two episodes of non-provoked VTE from patients with AMI with 100% accuracy (Fig 5A). We also show that a 60-gene classifier (validation 2) and a 23-gene classifier could discriminate patients with VTE and those with AMI from healthy individuals with an accuracy of 76.5% (Fig 5B) and 91.6% (Fig 5C) respectively. A classifier based on a gene set constituted of 76 commonly expressed genes were also capable to discriminate IS patients from healthy controls with 81.4% of precision (Fig 5D).
While both CVD and VTE are caused by the formation of thrombi inside a vessel, differences in their pathogenesis have been long recognized, with CVD linked to atherosclerosis [49] and VTE to the classical elements of the Virchow’s Triad [2, 50]. Yet, epidemiological, pathological and clinical data highlight the need for studies addressing in more detail the similarities and differences, particularly at the cellular and molecular level, between these two conditions. By using an integrative bioinformatics approach we were able to confirm that innate immunity, complement activation and classical hemostasis pathways are involved in the pathogenesis of both CVD and VTE at the transcriptomic level. In addition, we identified a shared and a discordant gene expression signature from VTE and CVD patients that can be used by other groups for the identification of biomarkers and therapeutic targets, as well as for a better understanding of the pathophysiology of these conditions.

**Discussion**

While both CVD and VTE are caused by the formation of thrombi inside a vessel, differences in their pathogenesis have been long recognized, with CVD linked to atherosclerosis [49] and VTE to the classical elements of the Virchow’s Triad [2, 50]. Yet, epidemiological, pathological and clinical data highlight the need for studies addressing in more detail the similarities and differences, particularly at the cellular and molecular level, between these two conditions. By using an integrative bioinformatics approach we were able to confirm that innate immunity, complement activation and classical hemostasis pathways are involved in the pathogenesis of both CVD and VTE at the transcriptomic level. In addition, we identified a shared and a discordant gene expression signature from VTE and CVD patients that can be used by other groups for the identification of biomarkers and therapeutic targets, as well as for a better understanding of the pathophysiology of these conditions.

![Fig 2. Fold-change of gene expression from patients with venous thromboembolism (VTE). Ischemic stroke (IS). Peripheral arterial occlusive disease (PAOD). Acute myocardial infarction (AMI). Cardioembolic stroke (CS). The top 20 up- (red) and down-regulated (blue) genes are listed.](https://doi.org/10.1371/journal.pone.0235501.g002)
VTE is a disease whose pathogenesis involves the interplay between venous stasis, hypercoagulability and endothelial damage. After more than a century since Virchow’s enumeration of these three elements, the concept of hypercoagulability and endothelial damage evolved substantially, and inflammation is currently recognized as a common cause of both alterations [51, 52]. According to this updated view, thrombo-inflammation, which involves leukocyte

![Fig 3. Heatmap built with the 124 DE genes that were divergently expressed between VTE and CVD. Each column represents an individual (control or patient) and conditions are shown in the upper row. Unsupervised clustering of these genes demonstrates that IS, MI and PAOD are clustered together, separately from VTE.](https://doi.org/10.1371/journal.pone.0235501.g003)
and platelet adhesion to the endothelium as well as local thrombin and fibrin generation, is part of a “biological response” that contributes to pathogen clearance and tissue repair, but that in the presence of prothrombotic factors (e.g. cancer, estrogens, etc) can tip the system towards a hypercoagulable state thereby triggering the cellular events of VTE [53–55]. On the other hand, the pathogenesis of CVD is intimately associated with atherogenesis, which involves (i) the recruitment, adherence and transmigration of circulating leukocytes to areas of endothelial damage; (ii) maturation of monocytes mature into macrophages in the intima which engulf low density lipoprotein molecules (originating foam cells); (iii) migration and proliferation of smooth muscle cells from the media into the intima, coupled with the synthesis of extracellular matrix molecules which contribute to the formation of the fibrous cap; and (iv) repeated cycles of proliferation and cell death inside the plaque which contribute to its growth and instability, and eventually lead to its physical rupture, which activates hemostasis (by tissue factor exposure and platelet activation), and ultimately results in thrombosis and ischemia [49, 52, 56].

Yet, several lines of evidence support an at least a partial overlap in the pathogenesis of VTE and CVD. From an epidemiological standpoint, this is well illustrated by a study that revealed that patients with unprovoked VTE present an estimated risk of atherosclerosis that is 5.1 and 14.5-fold higher than in patients with secondary VTE and healthy controls, respectively [7, 57] and by the existence of conditions that increase the risk of both VTE and CVD such as APS [58] and SCD [9, 59]. In addition, the cross-talk between the immune system, hemostasis and atherogenesis is being increasingly supported by experimental data [14, 15, 52, 60]. And finally, the classical borders between CVD and VTE were further blurred by results from large-scale
clinical trials in which aspirin was shown to decrease the risk of recurrent VTE [10, 11], and rivaroxaban, an anti-factor Xa anticoagulant was shown to decrease the risk of recurrent CVD more effectively than aspirin [12].

Using an integrative bioinformatics approach we analyzed five independent datasets of gene expression data and generated two distinct lists of genes that are commonly (n = 472) or divergently (n = 124) expressed in VTE and CVD. We took advantage of publicly available datasets from five well-designed studies addressing other scientific questions, but that generated high-quality data, all using the same microarray platform applied to both patients and healthy controls, and with sufficient meta-data to allow inter-study comparisons. We also took advantage of new standardized bioinformatics methods to perform data processing, meta-analyses and functional analyses [23, 61, 62].

Among commonly DE genes we observed a predominance of genes associated with innate immunity. These included genes that have been previously associated with CVD in human studies such as PTX3 (pentraxin 3) [63–65] and S100A12 (EN-RAGE) [66, 67], as well as genes that have been associated with CVD only in animal studies such as ANXA3 and SLPI, both shown to be up-regulated in rodent models of ischemic stroke [68, 69]. Our meta-analysis also identified a commonly down-regulated gene, ID3 (Inhibitor of DNA Binding 3. HLH Protein), which is atheroprotective in animal models [70] and whose functional polymorphisms have been associated with atherosclerosis protection in several populational studies [70, 71].
regard to VTE, *TBX21* (T-box 21), which was commonly down-regulated in our study, has been recently associated with the resolution of VTE in an animal model [72]. Though less frequent, genes that are more directly associated with hemostasis were also identified such as *SERPINB2* (plasminogen activator inhibitor 2), whose polymorphisms have been associated with recurrent CVD [73]. Finally, The identification of *BACH1* and *BACH2*, which are involved in heme metabolism, is also of interest since we and others have shown that heme is a potential activator of hemostasis [74–76]. The pattern observed in the analysis of individual DE genes was confirmed by the gene set analysis that identified pathways associated with hemostasis and innate immunity as the most consistently associated with the gene signature of VTE and CVD. Of note, pathways whose associations with the pathogenesis, diagnosis and even treatment of VTE/CVD were only recently confirmed, such as IL-1 signaling and neutrophil mediated immunity, emerged with strong associations in our model.

Genes whose expression was discordant between VTE and CVD were also explored, and in addition to a full list of these genes, we opted to identify pathways that were over-represented in VTE compared to CVD and vice versa. The most significant result was the identification of several neutrophil-related pathways in CVD when compared to VTE, suggesting a more prominent role for these cells in the former. Some of the genes involved in these pathways have been associated with CVD in animal models (*MCL1*, *JUND*, *PELI1*) [77–79], and in humans (*ACSL1*, *AOC3*, *ALPL*, *MMP9*, *PPIF*, *GRK2*) [80–87]. Also of interest was the identification of *PADI4*, a critical enzyme for the formation of neutrophil extracellular traps [88], which has been previously associated with other vascular-related phenotypes in animal models [89, 90].

These results are of interest for the following reasons: first, they represent a confirmation that the participation of innate immunity and hemostasis in the pathophysiology of VTE and CVD is also evident at the transcriptomic level, an observation that to our knowledge had not been previously demonstrated at a systems biology level; and second, the list of genes and pathways identified in our study (provided in detailed supplementary lists) may allow other groups to gain new insights about the pathophysiology of VTE and CVD at the cellular level and molecular level, as well as the identification of new biomarkers or therapeutic targets. In favor of this possibility is unsupervised call of the IL-1 pathway as a relevant pathway in the pathogenesis of CVD, which was recently confirmed by the CANTOS clinical trial [91], as well as the identification of complement, intrinsic prothrombin activation and neutrophil function as enriched pathways in both VTE and CVD, which is in accordance with new and evolving concepts of hemostasis and thrombosis [16, 92–94]. We also validated our results using a robust machine learning strategy in independent cohorts, by demonstrating that a list of 107 divergently expressed genes derived from our analysis was capable to discriminate with 100% accuracy patients with VTE and AMI. In addition, three other gene classifiers were constructed to discriminate patients with VTE, AMI and IS from healthy individuals with a precision of 76.5%, 91.6% and 81.4% respectively. While it should be emphasized that the objective of these validations is not to claim that these genes should be used to discriminate two conditions that are clearly defined by clinical characteristics, it does confirm that the experimental strategies used in our analyses are valid.

Our study has limitations that need to be acknowledged. As in any meta-analysis, results are dependent and limited by characteristics of the original studies. Even though we restricted our analysis to datasets used in peer-reviewed published studies, with high-quality meta-data and from the same microarray platform, only two studies involving VTE were available [40, 43], which were used as training and validation cohort. Since in both studies patients with cancer and APS were excluded, we believe that they although limited in number, they provide a good representation of VTE patients. The relative scarcity of microarray datasets was also the reason why we had to include studies using RNA from different sources (whole blood and...
PBMC), and with different time of sample collection since the index thrombotic event. In fact, this compromise between sample homogeneity and sample availability was necessary, or the study would not have been possible. Accordingly, we acknowledge that it is not possible to exclude that additional commonly expressed genes could have been identified if all datasets were from the same RNA source (type II error). On the other hand, since positive findings from our analytical approach were those that were remained significant in all samples despite this relative heterogeneity, our conclusions are likely to be of biological relevance (lower chance of type I error), as supported by our external validation. In fact, the concept of gene expression meta-analysis has been previously used in the context of other complex diseases [38, 95–97].

In conclusion, we demonstrate that the participation of innate immunity, complement and hemostasis activation in the pathogenesis of VTE and CVD is also evident at the transcriptomic level. We also demonstrate that in CVD, pathways associated with IL-1 signaling and neutrophil activation are relatively more represented in CVD than in VTE and that the gene expression signature of VTE resembles more closely the pattern observed in cardioembolic stroke than the pattern observed in AMI, IS or PAOD. Finally, we provide two validated lists of genes whose expression is shared or discordant between VTE and CVD, which can be used in future studies involving these two conditions.

Supporting information
S1 Table. List of all genes identified in the meta-analysis between VTE and CVD.
(DOCX)

S2 Table. Top differentially expressed genes identified in the meta-analysis of studies involving acute CVD.
(DOCX)

S3 Table. Top differentially expressed genes identified in the meta-analysis of studies involving chronic CVD.
(DOCX)

S4 Table. Divergently expressed genes in CVD and VTE.
(DOCX)

S5 Table. Genes that are up-regulated in CVD (vs VTE) expressed in neutrophils.
(XLSX)

S1 Fig. Correlation of gene expression changes studies of CVD whose samples were collected in the acute (a) or chronic (b) phase of their disease courses. Ischemic stroke (IS), Peripheral arterial occlusive disease (PAOD), Acute myocardial infarction (AMI) and Cardioembolic stroke (CS). Pairwise correlation scatter plots are in the lower triangle boxes. The upper triangle boxes show Pearson correlation coefficients (R) of log2 fold changes for all 472 differentially expressed genes identified in the meta-analysis of all 5 studies.
(DOCX)

Author Contributions
Conceptualization: Bidossessi Wilfried Hounkpe, Erich Vinicius De Paula.

Formal analysis: Bidossessi Wilfried Hounkpe.

Methodology: Bidossessi Wilfried Hounkpe, Rafaela de Oliveira Benatti.
Software: Benilton de Sá Carvalho.
Supervision: Erich Vinicius De Paula.
Writing – original draft: Rafaela de Oliveira Benatti.
Writing – review & editing: Erich Vinicius De Paula.

References
1. Wendelboe AM, Raskob GE. Global Burden of Thrombosis: Table. Circulation Research. 2016; 118: 1340–1347. https://doi.org/10.1161/CIRCRESAHA.115.306841 PMID: 27126645
2. Di Nisio M, van Es N, Bülter HR. Deep vein thrombosis and pulmonary embolism. Lancet (London, England). 2016; 388: 308–3073. https://doi.org/10.1016/S0140-6736(16)30514-1
3. Raskob G, Angchaisuknir P, Blanco A, AI E. Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol. 2014; 34: 2363–71. https://doi.org/10.1161/ATVBAHA.114.304488 PMID: 25304324
4. Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: A meta-analysis. Circulation. 2008; 117: 93–102. https://doi.org/10.1161/CIRCULATIONAHA.107.709204 PMID: 18086925
5. Srensen HT, Horvath-Puho E, Pedersen L, Baron JA, Prandoni P. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet. 2007; 370: 1773–1779. https://doi.org/10.1016/S0140-6736(07)61745-0 PMID: 18037081
6. Becattini C, Vedovati MC, Ageno W, Dentali F, Agnelli G. Incidence of arterial cardiovascular events after venous thromboembolism: A systematic review and a meta-analysis. Journal of Thrombosis and Haemostasis. 2010; 8: 891–897. https://doi.org/10.1111/j.1538-7836.2010.03777.x PMID: 20095999
7. Prandoni P, Milan M, Prandoni P, Milan M, Vedovetto V, Sarolo L, et al. Venous and Arterial Thromboembolism: Is there a Link? 2015. https://doi.org/10.1038/j.issn.2409-3548.2015.01.4
8. Saraiva SDS, Custódio IF, Mazetto BDM, Colella MP, De Paula EV, Appenzeller S, et al. Recurrent thrombosis in antiphospholipid syndrome may be associated with cardiovascular risk factors and inflammatory response. Thrombosis Research. 2015; 136: 1174–1178. https://doi.org/10.1016/j.thromres.2015.10.029 PMID: 26601900
9. Lim MY, Ataga KI, Key NS. Hemostatic abnormalities in sickle cell disease. Current opinion in hematology. 2013; 20: 472–7. https://doi.org/10.1097/MOH.0b013e328363442f PMID: 23817169
10. Brighton TA, Eikelboom JW, Mann K, Mister R, Gallus A, Ockelford P, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. The New England journal of medicine. 2012; 367: 1979–87. https://doi.org/10.1056/NEJMoa1210384 PMID: 23121403
11. Becattini C, Agnelli G, Schenone A, Eichinger S, Bucherini E, Silingardi M, et al. Aspirin for preventing the recurrence of venous thromboembolism. The New England journal of medicine. 2012; 366: 1959–67. https://doi.org/10.1056/NEJMoai114238 PMID: 22621626
12. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. The New England journal of medicine. 2017; 377: 1319–1330. https://doi.org/10.1056/NEJMoai1709118 PMID: 28641922
13. Lippi G, Favaloro EJ. Venous and Arterial Thromboses: Two Sides of the Same Coin? Semin Thromb Hemost. 2018; 44: 239–248. https://doi.org/10.1055/s-0037-1607202 PMID: 28946150
14. Spronk H, Padro T, Siland J, Prochaska J, Winters J, van der Wal A, et al. Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis, Thrombosis and Haemostasis. 2018; 118: 229–250. https://doi.org/10.1160/TH17-07-0492 PMID: 29378352
15. Borissoff J, Spronk H, ten Cate H. The Hemostatic System as a Modulator of Atherosclerosis. New England Journal of Medicine. 2011; 364: 1746–60. https://doi.org/10.1056/NEJMra101670 PMID: 21542745
16. Kreimers BMM, Birocchi S, van Oerle R, Zeerleder S, Spronk HM, Mees BME, et al. Searching for a Common Thrombo-Inflammatory Basis in Patients With Deep Vein Thrombosis or Peripheral Artery Disease. Frontiers in Cardiovascular Medicine. 2019; 6: 33. https://doi.org/10.3389/fcvm.2019.00033 PMID: 31001542
17. Wolberg AS, Rosendaal FR, Weitz JI, Jaffer IH, Agnelli G, Baglin T, et al. Venous thrombosis. Nature reviews Disease primers. 2015; 1: 15006. https://doi.org/10.1038/nrdp.2015.6 PMID: 27189130
18. Prandoni P, Bilora F, Marchiori A, Bernardi E, Petrobelli F, Lensing AWA, et al. An Association between Atherosclerosis and Venous Thrombosis. New England Journal of Medicine. 2003; 348: 1435–1441. https://doi.org/10.1056/NEJMoa022157 PMID: 12686699

19. Eliasson a, Bergqvist D, Björck M, Acosta S, Sternby NH, Ogren M. Incidence and risk of venous thromboembolism in patients with verified arterial thrombosis: a population study based on 27,996 consecutive autopsies. Journal of thrombosis and haemostasis: JTH. 2006; 4: 1897–902. https://doi.org/10.1111/j.1538-7836.2006.01215.x PMID: 16881933

20. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences. 2005; 102: 15545–15550. https://doi.org/10.1073/pnas.0506580102 PMID: 16199517

21. Alavi-Majd H, Khodakarim S, Zayeri F, Rezaei-Tavirani M, Tabatabaei SM, Heydarpour-Meymeh M. Assessment of gene set analysis methods based on microarray data. Gene. 2014; 534: 383–389. https://doi.org/10.1016/j.gene.2013.08.063 PMID: 24012817

22. Baker M. Gene data to hit milestone. Nature. 2012; 487: 282–283. https://doi.org/10.1038/487282a PMID: 22810669

23. Rung J, Brazma A. Reuse of public genome-wide gene expression data. Nature reviews Genetics. 2013; 14: 89–99. https://doi.org/10.1038/nrg3394 PMID: 23269463

24. Camacho DM, Collins KM, Powers RK, Costello JC, Collins JJ. Next-Generation Machine Learning for Biological Networks. Cell. 2018; 173: 1581–1592. https://doi.org/10.1016/j.cell.2018.05.015 PMID: 29887378

25. Yan J, Risacher SL, Shen L, Saykin AJ. Network approaches to systems biology analysis of complex disease: integrative methods for multi-omics data. Briefings in Bioinformatics. 2017; 19: 1370–1381. https://doi.org/10.1093/bib/btx066 PMID: 26679163

26. Wang Z, Wei Y, Zhang R, Su L, Gogarten SM, Liu G, et al. Multi-Omics Analysis Reveals a HIF Network and Hub Gene EPAS1 Associated with Lung Adenocarcinoma. EBioMedicine. 2018; 32: 93–101. https://doi.org/10.1016/j.ebiom.2018.05.024 PMID: 29859855

27. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. 2002; 30: 207–210.

28. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics (Oxford, England). 2003; 19: 185–93.

29. Carvalho BS, Irizarry RA. A framework for oligonucleotide microarray preprocessing. Bioinformatics. 2010; 26: 2363–2367. https://doi.org/10.1093/bioinformatics/btp431 PMID: 20688976

30. Durinck S, Spellman P, Birney E, Huber W. Mapping Identifiers for the Integration of Genomic Datasets with the R/Bioconductor package biomart. Nat Protoc. 2009; 4: 1184–91. https://doi.org/10.1038/nprot.2009.97 PMID: 19617889

31. Del Carratore F, Jankevics A, Eisinga R, Heskes T, Hong F, Breitling R. RankProd 2.0: a refactored bioconductor package for detecting differentially expressed features in molecular profiling datasets. Bioinformatics (Oxford, England). 2017; 33: 2774–2775. https://doi.org/10.1093/bioinformatics/btx292 PMID: 28481966

32. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria. 2018. https://doi.org/10.1108/eb003648

33. Mutch DM, Berger A, Mansourian R, Rytz A, Roberts MA. The limit fold change model: A practical approach for selecting differentially expressed genes from microarray data. BMC Bioinformatics. 2002. https://doi.org/10.1186/1471-2105-3-17 PMID: 12095422

34. Ronald J, Brem RB, Whittle J, Kruglyak L. Local regulatory variation in Saccharomyces cerevisiae. PLoS Genetics. 2005. https://doi.org/10.1371/journal.pgen.0010025 PMID: 16121257

35. Atai NA, Bansal M, Lo C, Bosman J, Tigchelaar W, Bosch KS, et al. Osteopontin is up-regulated and associated with neutrophil and macrophage infiltration in gliblastoma. Immunology. 2011. https://doi.org/10.1111/j.1365-2657.2010.03335.x PMID: 20722758

36. Wang B, Cunningham JM, Yang XH. Seq2pathway: an R/Bioconductor package for pathway analysis of next-generation sequencing data. Bioinformatics (Oxford, England). 2015; 31: 3043–5. https://doi.org/10.1093/bioinformatics/btv289 PMID: 25979472

37. Vapnik VN. An overview of statistical learning theory. IEEE transactions on neural networks. 1999; 10: 988–99. https://doi.org/10.1109/72.788640 PMID: 18252602

38. Jiang Y, Liu W, Li T, Hu Y, Chen S, Xi S, et al. Prognostic and Predictive Value of p21-activated Kinase 6 Associated Support Vector Machine Classifier in Gastric Cancer Treated by 5-fluorouracil/Oxaliplatin
Chemotherapy. EBioMedicine. 2017; 22: 78–88. https://doi.org/10.1016/j.ebiom.2017.06.028 PMID: 28687498

39. Yerukala Sathipati S, Ho S-Y. Identifying a miRNA signature for predicting the stage of breast cancer. Scientific Reports. 2018; 8: 16138. https://doi.org/10.1038/s41598-018-34604-3 PMID: 30382159

40. Lewis DA, Suchindran S, Beckman MG, Hooper WC, Grant AM, Heit JA, et al. Whole blood gene expression profiles distinguish clinical phenotypes of venous thromboembolism. Thrombosis research. 2015; 135: 659–65. https://doi.org/10.1016/j.thromres.2015.02.003 PMID: 25684211

41. Maciejak A, Kiliszek M, Michalak M, Tulacz D, Opolski G, Matlik K, et al. Gene expression profiling reveals potential prognostic biomarkers associated with the progression of heart failure. Genome Medicine. 2015; 7: 26. https://doi.org/10.1186/s13073-015-0149-z PMID: 25894239

42. Gu Z, Ellis R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics. 2016. https://doi.org/10.1093/bioinformatics/btw313 PMID: 27207943

43. Lewis DA, Stashenko GJ, Akay OM, Price Li, Ozzar K, Ginsburg GS, et al. Whole blood gene expression analyses in patients with single versus recurrent venous thromboembolism. Thrombosis research. 2011; 128: 536–40. https://doi.org/10.1016/j.thromres.2011.06.003 PMID: 21737128

44. Masud R, Shameer K, Dhar A, Ding K, Kullo IJ. Gene expression profiling of peripheral blood mononuclear cells in the setting of peripheral arterial disease. Journal of clinical bioinformatics. 2012; 2: 6. https://doi.org/10.1186/2043-9113-2-6 PMID: 22409835

45. Suresh R, Li X, Chiriac A, Goel K, Terzic A, Perez-Terzic C, et al. Transcriptome from circulating cells suggests dysregulated pathways associated with long-term recurrent events following first-time myocardial infarction. Journal of Molecular and Cellular Cardiology. 2014; 74: 13–21. https://doi.org/10.1016/j.jmcc.2014.04.017 PMID: 24801707

46. Stamova B, Jickling GC, Ander BP, Zhan X, Liu DZ, Turner R, et al. Gene expression in peripheral immune cells following cardioembolic stroke is sexually dimorphic. PLoS ONE. 2014; 9: 1–9. https://doi.org/10.1371/journal.pone.0102550 PMID: 25036109

47. Krug T, Gabriel JP, Taipa R, Fonseca B V, Domingues-Montanari S, Fernandez-Cadenas I, et al. TTC7B emerges as a novel risk factor for ischemic stroke through the convergence of several genome-wide approaches. Journal of Cerebral Blood Flow and Metabolism. 2012; 32: 1061–1072. https://doi.org/10.1038/jcbfm.2012.24 PMID: 22453632

48. Pancioli AM, Broderick J, Brott T, Tomsick T, Khoury J, Bean J, et al. The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial. Stroke. 2008; 39: 3268–76. https://doi.org/10.1161/STROKEAHA.108.517656 PMID: 18772447

49. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011; 473: 317–25. https://doi.org/10.1038/nature10146 PMID: 21593864

50. Virchow R. Thrombose und Embolie. Gefässentzündung und septische Infektion. Gesammelte Abhandlungen zur wissenschaftlichen Medicin. 1856; 219–732.

51. Albayati MA, Grover SP, Saha P, Lwaled BA, Modarai B, Smith A. Postsurgical Inflammation as a Causative Mechanism of Venous Thromboembolism. Seminars in thrombosis and hemostasis. 2015; 41: 615–20. https://doi.org/10.1055/s-0035-1556726 PMID: 26276933

52. Grover SP, Mackman N. Tissue Factor: An Essential Mediator of Hemostasis and Trigger of Thrombosis. Arteriosclerosis, thrombosis, and vascular biology. 2018; 38: 709–725. https://doi.org/10.1161/ATVBAHA.117.309846 PMID: 29437578

53. Engelsmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nature reviews Immunology. 2013; 13: 34–45. https://doi.org/10.1038/nri3345 PMID: 23222502

54. Mackman N. Science in medicine New insights into the mechanisms of venous thrombosis. 2012; 122: 2331–2336. https://doi.org/10.1177/JCI60229.paralysis

55. Versteeg HH, Heemskerk JWM, Levi M, Reitsma PH. New fundamentals in hemostasis. Physiological reviews. 2013; 93: 327–58. https://doi.org/10.1152/physrev.00016.2011 PMID: 23303912

56. Saleh M, Ambrose JA. Understanding myocardial infarction. F1000Research. 2018; 7: 1378. https://doi.org/10.12688/f1000research.15096.1 PMID: 30228871

57. Milan M, Vedovetto V, Bilora F, Pesavento R, Prandoni P. Further evidence in support of the association between venous thrombosis and atherosclerosis: a case-control study. Thromb Res. 2015; 134: 1028–31. https://doi.org/10.1016/j.thromres.2014.09.007 PMID: 25248667

58. Garcia D, Erkan D. Diagnosis and Management of the Antiphospholipid Syndrome. Longo DL, editor. The New England journal of medicine. 2018; 378: 2010–2021. https://doi.org/10.1056/NEJMra1705454 PMID: 29791828

59. Nouboussie D, Key NS, Ataga KI. Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies. Blood Reviews. 2015. https://doi.org/10.1016/j.blrev.2015.12.003 PMID: 26776344
60. Fiusa MML, Carvalho-Filho MA, Annichino-Bizzacchi JM, De Paula E V. Causes and consequences of coagulation activation in sepsis: an evolutionary medicine perspective. BMC medicine. 2015; 13: 105. https://doi.org/10.1186/12916-015-0327-2 PMID: 25943883

61. Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC bioinformatics. 2013; 14: 128. https://doi.org/10.1186/1471-2105-14-128 PMID: 23586463

62. Ramasamy A, Mondry A, Holmes CC, Altman DG. Key issues in conducting a meta-analysis of gene expression microarray datasets. PLoS Medicine. 2008; 5: 1320–1332. https://doi.org/10.1371/journal.pmed.0050184 PMID: 18767902

63. Jenny NS, Blumenthal RS, Kronmal RA, Rotter JI, Siscovick DS, Psaty BM. Associations of pentraxin 3 with cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis. Journal of thrombosis and hemostasis. JTH. 2014; 12: 999–1005. https://doi.org/10.1111/j.1538-7836.2013.04577.x PMID: 24628740

64. Jenny NS, Arnold AM, Kuller LH, Tracy RP, Psaty BM. Associations of Pentraxin 3 With Cardiovascular Disease and All-Cause Death. Arteriosclerosis, Thrombosis, and Vascular Biology. 2009; 29: 594–599. https://doi.org/10.1161/ATVBAHA.108.178947 PMID: 19164811

65. Ristagno G, Fumagalli F, Bottazzi B, Mantovani A, Olivari D, Novelli D, et al. Pentraxin 3 in Cardiovascular Disease. Frontiers in immunology. 2019; 10: 823. https://doi.org/10.3389/fimmu.2019.00823 PMID: 31057548

66. Shiotsu Y, Mori Y, Nishimura M, Sakoda C, Tokoro T, Hatta T, et al. Plasma S100A12 Level Is Associated with Cardiovascular Disease in Hemodialysis Patients. Clinical journal of the American Society of Nephrology. 2011; 6: 718–723. https://doi.org/10.2215/CJN.08310910 PMID: 21258041

67. Grauen Larsen H, Yndigegen T, Marinkovic G, Grufman H, Mares R, Nilsson J, et al. The soluble receptor for advanced glycation end-products (sRAGE) has a dual phase-dependent association with residual cardiovascular risk after an acute coronary event. Atherosclerosis. 2019; 287: 16–23. https://doi.org/10.1016/j.atherosclerosis.2019.05.020 PMID: 31181415

68. Wang X, Li X, Xu L, Zhan Y, Yaish-Ohad S, Erhardt JA, et al. Up-regulation of secretory leukocyte protease inhibitor-2 polymorphism-associated recurrent cardiovascular disease risk in patients with high HDL cholesterol and inflammation. Atherosclerosis. 2016; 250: 1–8. https://doi.org/10.1016/j.atherosclerosis.2019.05.020 PMID: 31181415

69. Kessler C, Junker H, Băleşeanu T-A, Oprea B, Pirici D, Mogoantă L, et al. Annexin A3 expression after stroke in the aged rat brain. Romanian journal of medicine and embryology – Revue romaine de morphologie et embryologie. 2008; 49: 27–35. PMID: 18273499

70. Doran AC, Lehtinen AB, Rotter JI, Siscovick DS, Psaty BM. Id3 is associated with coronary artery disease. Am J Epidemiol. 2020; 191: 1352–1361. https://doi.org/10.1093/aje/kwaa080 PMID: 32257888

71. Corsetti JP, Salzman P, Ryan D, Moss AJ, Zareba W, Eaker ED, et al. Excess inflammatory cytokine production in the plasma of patients with stable coronary artery disease. J Thromb Thrombolysis. 2016; 41: 309–313. https://doi.org/10.1007/s11239-015-1322-z PMID: 26848000

72. Chang SF, Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC bioinformatics. 2013; 14: 128. https://doi.org/10.1186/1471-2105-14-128 PMID: 23586463

73. Frieler RA, Chung Y, Ahlers CG, Gheordunescu G, Song J, Vigil TM, et al. Genetic neutrophil deficiency ameliorates cerebral ischemia-reperfusion injury. Experimental Neurology. 2017; 298: 104–111. https://doi.org/10.1016/j.expneurol.2017.08.016 PMID: 28865993
78. Wu W, Hu Y, Li J, Zhu W, Ha T, Que L, et al. Silencing of Pellino1 improves post-infarct cardiac dysfunction and attenuates left ventricular remodelling in mice. Cardiovascular Research. 2014; 102: 46–55. https://doi.org/10.1093/cvr/cvu007 PMID: 24442869

79. Diaz-Cañestro C, Reiner MF, Bonetti NR, Liberale L, Merlini W, Wüst P, et al. AP-1 (Activated Protein-1) Transcription Factor JunD Regulates Ischemia/Reperfusion Brain Damage via IL-1β (Interleukin-1β). Stroke. 2019; 50: 469–477. https://doi.org/10.1161/STROKEAHA.118.023739 PMID: 30626291

80. Campo G, Pavasini R, Pollina A, Fileti L, Marchesini J, Tebaldi M, et al. Thrombin generation assay: a new tool to predict and optimize clinical outcome in cardiovascular patients? Blood coagulation & fibrinolysis: an international journal in haemostasis and thrombosis. 2012; 23: 680–7. https://doi.org/10.1097/MBC.0b013e3283551111 PMID: 22688556

81. Manichaikul A, Wang X-Q, Zhao W, Wojczynski MK, Siebert R, Stamatoyannopoulos JA, et al. Genetic association of long-chain acyl-CoA synthetase 1 variants with fasting glucose, diabetes, and subclinical atherosclerosis. Journal of Lipid Research. 2016; 57: 433–442. https://doi.org/10.1194/jlr.M064592 PMID: 26711198

82. Kanter JE, Kramer F, Barmhart S, Averill MM, Vivekanandan-Giri A, Vickyery T, et al. Diabetes promotes an inflammatory macrophage phenotype and atherosclerosis through acyl-CoA synthetase 1. Proceedings of the National Academy of Sciences. 2012; 109: E715–E724. https://doi.org/10.1073/pnas.1111600109 PMID: 22390341

83. Li H-Y, Jiang Y-D, Chang T-J, Wei J-N, Lin M-S, Lin C-H, et al. Serum Vascular Adhesion Protein-1 Pre-oxygenation: An Early Predictor of Intraoperative Hemodynamic Instability and Postoperative Acute Kidney Injury in Patients Undergoing Major Vascular Surgery. Frontiers in Pharmacology. 2019; 10. https://doi.org/10.3389/fphar.2019.00112 PMID: 30837788

84. Misra S, Talwar P, Kumar A, Kumar P, Sagar R, Vibha D, et al. Association between matrix metalloproteinase family gene polymorphisms and risk of ischemic stroke: A systematic review and meta-analysis of 29 studies. Gene. 2018; 672: 180–194. https://doi.org/10.1016/j.gene.2018.06.027 PMID: 29906531

85. Fernández-Sanleón A, Sayols-Baixeras S, Curcio S, Subirana I, Marrugat J, Elosua R. DNA Methylation of the SH3PXD2B Gene and Its Potential as a Prognostic and Predictive Factor in Estrogen-Positive Breast Cancer: A Three-Country (REgistre Gironí del COR) Study. Arteriosclerosis, thrombosis, and vascular biology. 2018; 38: 645–652. https://doi.org/10.1161/ATVBAHA.117.310340 PMID: 29326313

86. Murga C, Arcones AC, Cruces-Sande M, Briones AM, Salaices M, Mayor F Jr. G Protein-Coupled Receptor Kinase 2 (GRK2) as a Potential Therapeutic Target in Cardiovascular and Metabolic Diseases. Frontiers in Pharmacology. 2019; 10. https://doi.org/10.3389/fphar.2019.00112 PMID: 30837788

87. Li P, Li M, Lindberg MR, Kennett MJ, Xiong N, Wang Y. PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps. The Journal of experimental medicine. 2010; 207: 1853–1862. https://doi.org/10.1084/jem.20100239 PMID: 20733033

88. Wong SL, Demers M, Martinod K, Gallant M, Wang Y, Goldfine AB, et al. Diabetes primes neutrophils to undergo NETosis, which impairs wound healing. Nature medicine. 2015; 21: 815–819. https://doi.org/10.1038/nn.3887 PMID: 26076037

89. Gollomp K, Kim M, Johnston I, Hayes V, Welsh J, Arepally GM, et al. Neutrophil accumulation and NET release contribute to thrombosis in HIT. JCI Insight. 2018; 3. https://doi.org/10.1172/jci.insight.99445 PMID: 30232279

90. Richardson PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantine C, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. New England Journal of Medicine. 2017; 377: 1119–1131. https://doi.org/10.1056/NEJMoa1707914 PMID: 28847571

91. Maas C, Renné T. Coagulation Factor XII in Thrombosis and Inflammation, Blood. 2018; 131: 1903–1909. https://doi.org/10.1182/blood-2017-04-659111 PMID: 29483100

92. Campello E, Henderson MW, Noubouossie DF, Simioni P, Key NS. Contact System Activation and Cancer: New Insights in the Pathophysiology of Cancer-Associated Thrombosis. Thrombosis and Haemostasis. 2018; 118: 251–265. https://doi.org/10.1160/TH17-08-0596 PMID: 29378353

93. Noubouossie DF, Reeves BN, Strahl BD, Key NS. Neutrophils: back in the thrombosis spotlight. Blood. 2019; blood-2018-10-862243. https://doi.org/10.1182/blood-2018-10-862243 PMID: 30898858

94. Kodama K, Toda K, Morinaga S, Yamada S, Butte AJ. Anti-CD44 Antibody Treatment Lowers Hyperglycemia and Improves Insulin Resistance, Adipose Inflammation, and Hepatic Steatosis in Diet-Induced Obese Mice. Diabetes. 2014; 63: 1119–1131. https://doi.org/10.2337/db13-1282 PMID: 24832279

95. Shimizu H, Nakayama KI. A 23 gene-based molecular prognostic score precisely predicts overall survival of breast cancer patients. EBioMedicine. 2019; 46: 150–159. https://doi.org/10.1016/j.ebiom.2019.07.046 PMID: 31358476
Hou Q, Bing Z-T, Hu C, Li M-Y, Yang K-H, Mo Z, et al. RankProd Combined with Genetic Algorithm Optimized Artificial Neural Network Establishes a Diagnostic and Prognostic Prediction Model that Revealed C1QTNF3 as a Biomarker for Prostate Cancer. EBioMedicine. 2018; 32: 234–244. https://doi.org/10.1016/j.ebiom.2018.05.010 PMID: 29861410